cadia Pharmaceuticals (ACAD) either didn’t receive — or is ignoring — the Big Pharma etiquette memo about easing back on egregious drug-price hikes.

During the fourth quarter, the San Diego-based company acknowledged Tuesday night, it took two price increases for Nuplazid, a pill used to quell hallucinations and delusions often experienced by people with advanced Parkinson’s disease.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.